DDInter107 DDInter1676
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements. It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors. In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or. Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Apalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eplerenone
Apalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Polatuzumab vedotin
Apalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anisindione
Apalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Delafloxacin
Apalutamide {u} may lead to a major life threatening interaction when taken with {v} Isavuconazonium
Apalutamide {u} may lead to a major life threatening interaction when taken with {v} Abemaciclib
Apalutamide may cause a minor interaction that can limit clinical effects when taken with Eplerenone
Apalutamide may cause a minor interaction that can limit clinical effects when taken with Polatuzumab vedotin
Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin
Apalutamide may lead to a major life threatening interaction when taken with Isavuconazonium
Apalutamide may lead to a major life threatening interaction when taken with Abemaciclib